Ikatibant Fresenius (Icatibant Acetate)

Icatibant Acetate is used to manage bradykinin‑mediated swelling disorders, particularly hereditary angioedema.

• Hereditary angioedema (HAE) type I and II: Reduces swelling and shortens the duration of acute attacks.
• Acute bradykinin‑mediated angioedema: Provides rapid symptom relief during sudden episodes.
• HAE with C1‑esterase inhibitor deficiency: Restores normal vascular permeability during crises.

• Icatibant Acetate selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and activating the receptor. This inhibition stops bradykinin‑induced vasodilation and increased vascular permeability, thereby reducing the swelling and pain associated with hereditary angioedema attacks.

Icatibant Acetate may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

• Injection site pain: Discomfort at the site of subcutaneous administration.
• Redness or erythema: Localized skin irritation.
• Swelling at injection site: Mild to moderate edema.
• Nausea: Transient gastrointestinal upset.
• Headache: Mild to moderate intensity.
• Dizziness: Transient sensation of light‑headedness.

Serious or Rare Side Effects

• Hypersensitivity reactions: Rash, itching, or hives.
• Anaphylaxis: Severe, potentially life‑threatening allergic response.
• Severe hypotension: Marked drop in blood pressure.
• Angioedema unrelated to HAE: Unexpected swelling in other areas.
• Thrombocytopenia: Low platelet count.
• Injection‑site infection: Signs of local infection such as warmth or pus.

Before using Icatibant Acetate, consider the following safety measures.

• Renal impairment: Monitor renal function and adjust therapy as needed.
• Hepatic impairment: Use with caution and observe liver function tests.
• Pregnancy: Safety not established; weigh potential benefits against risks.
• Concomitant ACE inhibitors or ARBs: May increase bradykinin levels; monitor for angioedema.
• Known hypersensitivity: Discontinue immediately if allergic reaction occurs.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant Acetate can interact with other medications that influence the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid)

• ACE inhibitors: Heightened risk of angioedema.
• Angiotensin receptor blockers (ARBs): May amplify bradykinin‑mediated effects.
• Other bradykinin‑targeting agents: Additive blockade could cause unexpected reactions.

Moderate Interactions (Monitor Closely)

• Diuretics: Observe blood pressure and electrolyte balance.
• Antihistamines: May mask early signs of hypersensitivity.
• NSAIDs: Monitor for increased swelling or pain at injection site.